|Articles|October 14, 2019
Quantifying Quality Attributes of AAV Gene Therapy Vectors by SEC-UV-MALS-dRI
Author(s)Wyatt
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Developing Next-Gen Cell Lines Using Targeted Integration
2
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
3
FAQ: What You Need to Know about the Current Antibody Pipeline
4
Norgine Secures Hepatitis Delta Therapy Rights Across Key Region
5